\babel@toc {english}{}\relax 
\contentsline {part}{I\hspace {1em}Notes}{7}{part.1}%
\contentsline {chapter}{\numberline {1}Introduction}{8}{chapter.1}%
\contentsline {section}{\numberline {1.1}Genetics and genomics}{8}{section.1.1}%
\contentsline {subsection}{\numberline {1.1.1}Genetics}{8}{subsection.1.1.1}%
\contentsline {subsection}{\numberline {1.1.2}Genomics}{8}{subsection.1.1.2}%
\contentsline {subsection}{\numberline {1.1.3}Differences between genetics and genomics}{8}{subsection.1.1.3}%
\contentsline {subsection}{\numberline {1.1.4}The role of computational biology}{9}{subsection.1.1.4}%
\contentsline {section}{\numberline {1.2}Basis of human genomics}{9}{section.1.2}%
\contentsline {subsection}{\numberline {1.2.1}Single nucleotide polymorphisms}{9}{subsection.1.2.1}%
\contentsline {subsection}{\numberline {1.2.2}Copy number variants}{9}{subsection.1.2.2}%
\contentsline {subsection}{\numberline {1.2.3}Inherited variants}{9}{subsection.1.2.3}%
\contentsline {subsubsection}{\numberline {1.2.3.1}Penetrance}{10}{subsubsection.1.2.3.1}%
\contentsline {subsubsection}{\numberline {1.2.3.2}Allele frequency}{10}{subsubsection.1.2.3.2}%
\contentsline {subsubsection}{\numberline {1.2.3.3}Differences in Genetic Make-Up, an example}{10}{subsubsection.1.2.3.3}%
\contentsline {subsection}{\numberline {1.2.4}Somatic Variants}{11}{subsection.1.2.4}%
\contentsline {subsubsection}{\numberline {1.2.4.1}Classification}{11}{subsubsection.1.2.4.1}%
\contentsline {subsubsection}{\numberline {1.2.4.2}Types of acquired DNA aberrations}{11}{subsubsection.1.2.4.2}%
\contentsline {paragraph}{\numberline {1.2.4.2.1}Translocation}{11}{paragraph.1.2.4.2.1}%
\contentsline {paragraph}{\numberline {1.2.4.2.2}Inversion}{11}{paragraph.1.2.4.2.2}%
\contentsline {paragraph}{\numberline {1.2.4.2.3}Copy number changes}{12}{paragraph.1.2.4.2.3}%
\contentsline {paragraph}{\numberline {1.2.4.2.4}Chromoplexy}{12}{paragraph.1.2.4.2.4}%
\contentsline {section}{\numberline {1.3}Experimental techniques to detect variants/aberrations}{12}{section.1.3}%
\contentsline {subsection}{\numberline {1.3.1}Karyotyping}{12}{subsection.1.3.1}%
\contentsline {subsection}{\numberline {1.3.2}Sequence capture for cancer genomics}{12}{subsection.1.3.2}%
\contentsline {subsubsection}{\numberline {1.3.2.1}Reference}{12}{subsubsection.1.3.2.1}%
\contentsline {subsubsection}{\numberline {1.3.2.2}Deepness}{13}{subsubsection.1.3.2.2}%
\contentsline {subsubsection}{\numberline {1.3.2.3}Single End (SE) and Paired End (PE) reads}{13}{subsubsection.1.3.2.3}%
\contentsline {paragraph}{\numberline {1.3.2.3.1}Single end sequencing}{13}{paragraph.1.3.2.3.1}%
\contentsline {paragraph}{\numberline {1.3.2.3.2}Paired end sequencing}{13}{paragraph.1.3.2.3.2}%
\contentsline {paragraph}{\numberline {1.3.2.3.3}Ability of paired end sequencing to detect genomic aberrations}{13}{paragraph.1.3.2.3.3}%
\contentsline {chapter}{\numberline {2}Coverage}{14}{chapter.2}%
\contentsline {section}{\numberline {2.1}Computing coverage}{14}{section.2.1}%
\contentsline {subsection}{\numberline {2.1.1}Local coverage}{14}{subsection.2.1.1}%
\contentsline {subsection}{\numberline {2.1.2}Allelic fraction}{14}{subsection.2.1.2}%
\contentsline {subsection}{\numberline {2.1.3}NGS global coverage}{14}{subsection.2.1.3}%
\contentsline {section}{\numberline {2.2}Mapping in NGS}{14}{section.2.2}%
\contentsline {subsection}{\numberline {2.2.1}Sequence coverage}{15}{subsection.2.2.1}%
\contentsline {subsection}{\numberline {2.2.2}Physical coverage}{15}{subsection.2.2.2}%
\contentsline {section}{\numberline {2.3}Tuning coverage}{15}{section.2.3}%
\contentsline {subsection}{\numberline {2.3.1}SNP detection}{15}{subsection.2.3.1}%
\contentsline {subsection}{\numberline {2.3.2}Subclonal events}{15}{subsection.2.3.2}%
\contentsline {subsection}{\numberline {2.3.3}Amplicon-based approaches}{16}{subsection.2.3.3}%
\contentsline {subsubsection}{\numberline {2.3.3.1}Heterozygous deletion of PTEN}{16}{subsubsection.2.3.3.1}%
\contentsline {subsubsection}{\numberline {2.3.3.2}Homozygous deletion of PTEN}{16}{subsubsection.2.3.3.2}%
\contentsline {subsubsection}{\numberline {2.3.3.3}Amplification of AR}{16}{subsubsection.2.3.3.3}%
\contentsline {subsection}{\numberline {2.3.4}NGS-based approaches}{17}{subsection.2.3.4}%
\contentsline {subsubsection}{\numberline {2.3.4.1}Advantages over amplicon-based approaches}{17}{subsubsection.2.3.4.1}%
\contentsline {subsubsection}{\numberline {2.3.4.2}Problems of NGS-based approaches}{17}{subsubsection.2.3.4.2}%
\contentsline {section}{\numberline {2.4}Databases for NGS analysis}{17}{section.2.4}%
\contentsline {subsection}{\numberline {2.4.1}Genome reference consortium}{17}{subsection.2.4.1}%
\contentsline {subsection}{\numberline {2.4.2}USCS genome browser}{17}{subsection.2.4.2}%
\contentsline {chapter}{\numberline {3}Genetic Fingerprinting}{18}{chapter.3}%
\contentsline {section}{\numberline {3.1}Introduction}{18}{section.3.1}%
\contentsline {subsection}{\numberline {3.1.1}Fields of interest}{18}{subsection.3.1.1}%
\contentsline {subsection}{\numberline {3.1.2}Variants used for genetic testing}{18}{subsection.3.1.2}%
\contentsline {subsubsection}{\numberline {3.1.2.1}CNVs}{18}{subsubsection.3.1.2.1}%
\contentsline {subsubsection}{\numberline {3.1.2.2}SNPs}{19}{subsubsection.3.1.2.2}%
\contentsline {section}{\numberline {3.2}SNPs features}{19}{section.3.2}%
\contentsline {subsection}{\numberline {3.2.1}Hardy-Weinberg equilibrium}{19}{subsection.3.2.1}%
\contentsline {subsection}{\numberline {3.2.2}Minor allele frequency}{19}{subsection.3.2.2}%
\contentsline {subsubsection}{\numberline {3.2.2.1}Optimal MAF values for genetic fingerprinting}{19}{subsubsection.3.2.2.1}%
\contentsline {subsection}{\numberline {3.2.3}Haplotype blocks}{20}{subsection.3.2.3}%
\contentsline {subsubsection}{\numberline {3.2.3.1}Linkage disequilibrium}{20}{subsubsection.3.2.3.1}%
\contentsline {subsubsection}{\numberline {3.2.3.2}Tag SNPs}{20}{subsubsection.3.2.3.2}%
\contentsline {subsection}{\numberline {3.2.4}Other SNP features}{21}{subsection.3.2.4}%
\contentsline {subsection}{\numberline {3.2.5}Number of SNPs to select when performing a genetic test}{21}{subsection.3.2.5}%
\contentsline {subsubsection}{\numberline {3.2.5.1}Experimental mismatches - Genotype call error rate}{21}{subsubsection.3.2.5.1}%
\contentsline {paragraph}{\numberline {3.2.5.1.1}An example on the effect of experimental mismatches}{22}{figure.caption.12}%
\contentsline {subsubsection}{\numberline {3.2.5.2}Biological mismatches}{22}{subsubsection.3.2.5.2}%
\contentsline {paragraph}{\numberline {3.2.5.2.1}Loss of Heterozygosity (LOH)}{22}{paragraph.3.2.5.2.1}%
\contentsline {paragraph}{\numberline {3.2.5.2.2}Gain Of Heterozygosity (GOH)}{22}{paragraph.3.2.5.2.2}%
\contentsline {paragraph}{\numberline {3.2.5.2.3}Double Mutation (DM)}{22}{paragraph.3.2.5.2.3}%
\contentsline {paragraph}{\numberline {3.2.5.2.4}Modelling biological mismatches}{22}{paragraph.3.2.5.2.4}%
\contentsline {subsection}{\numberline {3.2.6}Project regarding SNPs}{23}{subsection.3.2.6}%
\contentsline {subsubsection}{\numberline {3.2.6.1}dbSNPs}{23}{subsubsection.3.2.6.1}%
\contentsline {subsubsection}{\numberline {3.2.6.2}HapMap3}{23}{subsubsection.3.2.6.2}%
\contentsline {section}{\numberline {3.3}Genetic distance}{23}{section.3.3}%
\contentsline {subsection}{\numberline {3.3.1}Measuring distance}{23}{subsection.3.3.1}%
\contentsline {subsubsection}{\numberline {3.3.1.1}Expected distance}{25}{subsubsection.3.3.1.1}%
\contentsline {subsubsection}{\numberline {3.3.1.2}Identifying a sample origin from RAP samples}{26}{subsubsection.3.3.1.2}%
\contentsline {subsection}{\numberline {3.3.2}Distance changes with different numbers of SNPs}{27}{subsection.3.3.2}%
\contentsline {section}{\numberline {3.4}Building a SNP-based genetic test}{27}{section.3.4}%
\contentsline {subsection}{\numberline {3.4.1}Pipeline}{27}{subsection.3.4.1}%
\contentsline {subsection}{\numberline {3.4.2}Implementation of a probabilistic test to identify samples}{28}{subsection.3.4.2}%
\contentsline {subsubsection}{\numberline {3.4.2.1}Classification}{28}{subsubsection.3.4.2.1}%
\contentsline {subsection}{\numberline {3.4.3}Some examples of genetic tests}{29}{subsection.3.4.3}%
\contentsline {subsubsection}{\numberline {3.4.3.1}Investigating cell line passages}{29}{subsubsection.3.4.3.1}%
\contentsline {subsubsection}{\numberline {3.4.3.2}Investigating individual relatedness}{29}{subsubsection.3.4.3.2}%
\contentsline {subsection}{\numberline {3.4.4}Genetic structure of the human population}{30}{subsection.3.4.4}%
\contentsline {subsubsection}{\numberline {3.4.4.1}Genes mirror geography in Europe}{31}{subsubsection.3.4.4.1}%
\contentsline {chapter}{\numberline {4}IGV (Integrative Genomics Viewer)}{33}{chapter.4}%
\contentsline {section}{\numberline {4.1}IGV characteristics}{33}{section.4.1}%
\contentsline {subsection}{\numberline {4.1.1}Introduction}{33}{subsection.4.1.1}%
\contentsline {subsection}{\numberline {4.1.2}Main uses of IGV}{33}{subsection.4.1.2}%
\contentsline {subsubsection}{\numberline {4.1.2.1}RNA sequence analysis}{34}{subsubsection.4.1.2.1}%
\contentsline {subsubsection}{\numberline {4.1.2.2}Variant discovery}{35}{subsubsection.4.1.2.2}%
\contentsline {subsection}{\numberline {4.1.3}Operations}{35}{subsection.4.1.3}%
\contentsline {subsection}{\numberline {4.1.4}Tiles}{36}{subsection.4.1.4}%
\contentsline {subsubsection}{\numberline {4.1.4.1}Pixel resolution error}{36}{subsubsection.4.1.4.1}%
\contentsline {subsubsection}{\numberline {4.1.4.2}Data displayed at different resolutions}{37}{subsubsection.4.1.4.2}%
\contentsline {subsection}{\numberline {4.1.5}IGVTools}{37}{subsection.4.1.5}%
\contentsline {subsection}{\numberline {4.1.6}Session files}{37}{subsection.4.1.6}%
\contentsline {section}{\numberline {4.2}Interpreting pair orientations}{38}{section.4.2}%
\contentsline {subsection}{\numberline {4.2.1}Element to consider when interpreting pair orientations}{38}{subsection.4.2.1}%
\contentsline {subsection}{\numberline {4.2.2}Inversion}{38}{subsection.4.2.2}%
\contentsline {subsection}{\numberline {4.2.3}Tandem duplication}{39}{subsection.4.2.3}%
\contentsline {subsection}{\numberline {4.2.4}Inverted duplication}{39}{subsection.4.2.4}%
\contentsline {subsection}{\numberline {4.2.5}Deletion}{40}{subsection.4.2.5}%
\contentsline {section}{\numberline {4.3}Uncovering genetic aberrations - some examples}{40}{section.4.3}%
\contentsline {subsection}{\numberline {4.3.1}First example}{40}{subsection.4.3.1}%
\contentsline {subsection}{\numberline {4.3.2}Second example}{40}{subsection.4.3.2}%
\contentsline {subsection}{\numberline {4.3.3}Third example}{41}{subsection.4.3.3}%
\contentsline {chapter}{\numberline {5}Tumor Evolution Studies via NGS data}{43}{chapter.5}%
\contentsline {section}{\numberline {5.1}Tumour evolution}{43}{section.5.1}%
\contentsline {subsection}{\numberline {5.1.1}Introduction}{43}{subsection.5.1.1}%
\contentsline {subsubsection}{\numberline {5.1.1.1}Typical traits of cancer}{43}{subsubsection.5.1.1.1}%
\contentsline {subsubsection}{\numberline {5.1.1.2}Tumour boards}{43}{subsubsection.5.1.1.2}%
\contentsline {subsection}{\numberline {5.1.2}Heterogeneity}{44}{subsection.5.1.2}%
\contentsline {subsubsection}{\numberline {5.1.2.1}Temporal heterogeneity}{44}{subsubsection.5.1.2.1}%
\contentsline {subsubsection}{\numberline {5.1.2.2}Spatial heterogeneity}{44}{subsubsection.5.1.2.2}%
\contentsline {subsection}{\numberline {5.1.3}Type of evolutions}{44}{subsection.5.1.3}%
\contentsline {subsubsection}{\numberline {5.1.3.1}Linear evolution}{45}{subsubsection.5.1.3.1}%
\contentsline {subsubsection}{\numberline {5.1.3.2}Branched evolution}{45}{subsubsection.5.1.3.2}%
\contentsline {subsection}{\numberline {5.1.4}Treatment resistance}{45}{subsection.5.1.4}%
\contentsline {subsubsection}{\numberline {5.1.4.1}Primary resistance}{46}{subsubsection.5.1.4.1}%
\contentsline {subsubsection}{\numberline {5.1.4.2}Acquired resistance}{46}{subsubsection.5.1.4.2}%
\contentsline {section}{\numberline {5.2}Using NGS data to uncover tumour evolution}{46}{section.5.2}%
\contentsline {subsection}{\numberline {5.2.1}Introduction}{46}{subsection.5.2.1}%
\contentsline {subsection}{\numberline {5.2.2}Admixture}{47}{subsection.5.2.2}%
\contentsline {subsection}{\numberline {5.2.3}Informative SNPs}{47}{subsection.5.2.3}%
\contentsline {subsection}{\numberline {5.2.4}Beta value}{48}{subsection.5.2.4}%
\contentsline {subsubsection}{\numberline {5.2.4.1}Computing beta}{49}{subsubsection.5.2.4.1}%
\contentsline {subsubsection}{\numberline {5.2.4.2}Effect of coverage on beta}{50}{subsubsection.5.2.4.2}%
\contentsline {subsection}{\numberline {5.2.5}Estimates of global and local admixture}{50}{subsection.5.2.5}%
\contentsline {subsubsection}{\numberline {5.2.5.1}Estimates of DNA admixture}{51}{subsubsection.5.2.5.1}%
\contentsline {subsection}{\numberline {5.2.6}PR-2741 - an example}{52}{subsection.5.2.6}%
\contentsline {chapter}{\numberline {6}Tumor evolution studies: copy number based methods}{54}{chapter.6}%
\contentsline {section}{\numberline {6.1}Analysis of clonality}{54}{section.6.1}%
\contentsline {subsection}{\numberline {6.1.1}Informative SNPs}{54}{subsection.6.1.1}%
\contentsline {subsection}{\numberline {6.1.2}Log2 ratio}{54}{subsection.6.1.2}%
\contentsline {subsection}{\numberline {6.1.3}Beta value}{55}{subsection.6.1.3}%
\contentsline {subsection}{\numberline {6.1.4}Cluster analysis in the beta-log2 ratio space}{55}{subsection.6.1.4}%
\contentsline {section}{\numberline {6.2}Evolution maps}{56}{section.6.2}%
\contentsline {subsection}{\numberline {6.2.1}Introduction}{56}{subsection.6.2.1}%
\contentsline {subsection}{\numberline {6.2.2}Building an evolution map}{56}{subsection.6.2.2}%
\contentsline {subsection}{\numberline {6.2.3}A toy example}{56}{subsection.6.2.3}%
\contentsline {subsection}{\numberline {6.2.4}A real world data example}{58}{subsection.6.2.4}%
\contentsline {subsubsection}{\numberline {6.2.4.1}Limitations}{58}{subsubsection.6.2.4.1}%
\contentsline {subsection}{\numberline {6.2.5}Pathway-based evolutionary maps}{58}{subsection.6.2.5}%
\contentsline {subsubsection}{\numberline {6.2.5.1}Timing}{59}{subsubsection.6.2.5.1}%
\contentsline {subsubsection}{\numberline {6.2.5.2}Treatment}{59}{subsubsection.6.2.5.2}%
\contentsline {section}{\numberline {6.3}Ploidy and purity corrections}{59}{section.6.3}%
\contentsline {subsection}{\numberline {6.3.1}Introduction}{59}{subsection.6.3.1}%
\contentsline {subsection}{\numberline {6.3.2}A melanoma example}{60}{subsection.6.3.2}%
\contentsline {subsubsection}{\numberline {6.3.2.1}Ploidy correction}{60}{subsubsection.6.3.2.1}%
\contentsline {subsubsection}{\numberline {6.3.2.2}Purity correction}{61}{subsubsection.6.3.2.2}%
\contentsline {subsection}{\numberline {6.3.3}A melanoma example considering more samples}{61}{subsection.6.3.3}%
\contentsline {subsection}{\numberline {6.3.4}An example with TGCA data}{62}{subsection.6.3.4}%
\contentsline {subsubsection}{\numberline {6.3.4.1}Ploidy correction}{62}{subsubsection.6.3.4.1}%
\contentsline {section}{\numberline {6.4}Allele-specific analysis}{63}{section.6.4}%
\contentsline {subsection}{\numberline {6.4.1}Introduction}{63}{subsection.6.4.1}%
\contentsline {subsection}{\numberline {6.4.2}An example}{64}{subsection.6.4.2}%
\contentsline {subsubsection}{\numberline {6.4.2.1}Changes of copy number for specific alleles}{65}{subsubsection.6.4.2.1}%
\contentsline {subsubsection}{\numberline {6.4.2.2}Copy number neutral events}{65}{subsubsection.6.4.2.2}%
\contentsline {subsection}{\numberline {6.4.3}A case study}{66}{subsection.6.4.3}%
\contentsline {subsubsection}{\numberline {6.4.3.1}Primary site}{67}{subsubsection.6.4.3.1}%
\contentsline {subsubsection}{\numberline {6.4.3.2}Metastasis}{67}{subsubsection.6.4.3.2}%
\contentsline {section}{\numberline {6.5}Longitudinal plasma profiling}{68}{section.6.5}%
\contentsline {subsection}{\numberline {6.5.1}An example}{68}{subsection.6.5.1}%
\contentsline {subsection}{\numberline {6.5.2}Tracking evolution}{69}{subsection.6.5.2}%
\contentsline {chapter}{\numberline {7}Tumor evolution studies: SNVs-based methods}{70}{chapter.7}%
\contentsline {section}{\numberline {7.1}Introduction}{70}{section.7.1}%
\contentsline {subsection}{\numberline {7.1.1}Copy-number neutral tumours}{70}{subsection.7.1.1}%
\contentsline {subsection}{\numberline {7.1.2}Different methods for tumour assessment}{71}{subsection.7.1.2}%
\contentsline {subsection}{\numberline {7.1.3}Rationale of SNV based methods}{71}{subsection.7.1.3}%
\contentsline {subsection}{\numberline {7.1.4}Advantages and limitations of SNVs based methods}{71}{subsection.7.1.4}%
\contentsline {subsection}{\numberline {7.1.5}Reference mapping bias}{72}{subsection.7.1.5}%
\contentsline {section}{\numberline {7.2}TPES - tumour purity estimation from SNVs}{72}{section.7.2}%
\contentsline {subsection}{\numberline {7.2.1}Introduction}{72}{subsection.7.2.1}%
\contentsline {subsection}{\numberline {7.2.2}SNV identification}{72}{subsection.7.2.2}%
\contentsline {subsubsection}{\numberline {7.2.2.1}Selection of copy-number neutral segments}{73}{subsubsection.7.2.2.1}%
\contentsline {subsubsection}{\numberline {7.2.2.2}Allelic fraction}{73}{subsubsection.7.2.2.2}%
\contentsline {subsubsection}{\numberline {7.2.2.3}Identification of putative clonal SNVs}{73}{subsubsection.7.2.2.3}%
\contentsline {subsection}{\numberline {7.2.3}Purity estimation}{73}{subsection.7.2.3}%
\contentsline {subsection}{\numberline {7.2.4}Minimal number of SNV for tumour identification}{73}{subsection.7.2.4}%
\contentsline {subsection}{\numberline {7.2.5}Comparison with other tumour callers}{74}{subsection.7.2.5}%
\contentsline {chapter}{\numberline {8}Liquid biopsies in oncology}{75}{chapter.8}%
\contentsline {section}{\numberline {8.1}Introduction}{75}{section.8.1}%
\contentsline {subsection}{\numberline {8.1.1}Tracking tumour progression}{75}{subsection.8.1.1}%
\contentsline {subsection}{\numberline {8.1.2}Differences between tissue and liquid biopsies}{75}{subsection.8.1.2}%
\contentsline {subsubsection}{\numberline {8.1.2.1}Liquid biopsies allow to perform a number of analysis}{76}{subsubsection.8.1.2.1}%
\contentsline {subsubsection}{\numberline {8.1.2.2}Material availability}{76}{subsubsection.8.1.2.2}%
\contentsline {subsubsection}{\numberline {8.1.2.3}Tumour content}{76}{subsubsection.8.1.2.3}%
\contentsline {subsubsection}{\numberline {8.1.2.4}Assessment of tumour ploidy}{76}{subsubsection.8.1.2.4}%
\contentsline {subsection}{\numberline {8.1.3}Application-dependent requirements}{77}{subsection.8.1.3}%
\contentsline {subsubsection}{\numberline {8.1.3.1}Early tumour, MRD and recurrence detection}{77}{subsubsection.8.1.3.1}%
\contentsline {subsubsection}{\numberline {8.1.3.2}Analysis of tumour dynamics, treatment response and analysis of the mechanisms of resistance}{77}{subsubsection.8.1.3.2}%
\contentsline {subsubsection}{\numberline {8.1.3.3}Single biomarker assessment}{77}{subsubsection.8.1.3.3}%
\contentsline {subsection}{\numberline {8.1.4}Whole-genome and targeted sequencing}{77}{subsection.8.1.4}%
\contentsline {subsection}{\numberline {8.1.5}Challenges in tracking tumour evolution with liquid biopsies}{78}{subsection.8.1.5}%
\contentsline {subsubsection}{\numberline {8.1.5.1}An example of similarity between two plasma samples between two different tumours}{78}{subsubsection.8.1.5.1}%
\contentsline {section}{\numberline {8.2}Interpretation of cell free DNA data}{78}{section.8.2}%
\contentsline {subsection}{\numberline {8.2.1}Introduction}{78}{subsection.8.2.1}%
\contentsline {subsection}{\numberline {8.2.2}Normalization}{78}{subsection.8.2.2}%
\contentsline {subsection}{\numberline {8.2.3}Quantity of input material}{79}{subsection.8.2.3}%
\contentsline {subsection}{\numberline {8.2.4}SNVs detection}{80}{subsection.8.2.4}%
\contentsline {subsubsection}{\numberline {8.2.4.1}Technical problems}{80}{subsubsection.8.2.4.1}%
\contentsline {subsubsection}{\numberline {8.2.4.2}Biological problems}{81}{subsubsection.8.2.4.2}%
\contentsline {subsection}{\numberline {8.2.5}Two case studies}{81}{subsection.8.2.5}%
\contentsline {subsubsection}{\numberline {8.2.5.1}Signal distribution in prostate cancer}{81}{subsubsection.8.2.5.1}%
\contentsline {subsubsection}{\numberline {8.2.5.2}Non-AR driven castration resistance prostate cancer}{81}{subsubsection.8.2.5.2}%
\contentsline {chapter}{\numberline {9}Extracellular vesicles}{83}{chapter.9}%
\contentsline {section}{\numberline {9.1}Definition}{83}{section.9.1}%
\contentsline {section}{\numberline {9.2}Characterization}{83}{section.9.2}%
\contentsline {subsection}{\numberline {9.2.1}Size}{84}{subsection.9.2.1}%
\contentsline {subsection}{\numberline {9.2.2}Origin}{84}{subsection.9.2.2}%
\contentsline {subsection}{\numberline {9.2.3}Content}{85}{subsection.9.2.3}%
\contentsline {section}{\numberline {9.3}The importance of EVs}{85}{section.9.3}%
\contentsline {subsection}{\numberline {9.3.1}Role in cancer}{85}{subsection.9.3.1}%
\contentsline {section}{\numberline {9.4}How can we use them to study cancer? (or any other disease)}{86}{section.9.4}%
\contentsline {subsection}{\numberline {9.4.1}Tracking tumor signal in serial samples}{87}{subsection.9.4.1}%
\contentsline {subsection}{\numberline {9.4.2}Different EVs isolation methods}{87}{subsection.9.4.2}%
\contentsline {chapter}{\numberline {10}Epigenetic profiling of cell-free DNA}{88}{chapter.10}%
\contentsline {section}{\numberline {10.1}Introduction}{88}{section.10.1}%
\contentsline {section}{\numberline {10.2}DNA methylation}{88}{section.10.2}%
\contentsline {section}{\numberline {10.3}How is DNA methylation measured?}{89}{section.10.3}%
\contentsline {section}{\numberline {10.4}Tissue-specific vs disease-specific DNA markers}{90}{section.10.4}%
\contentsline {section}{\numberline {10.5}DNA methylation based liquid biopsy}{90}{section.10.5}%
\contentsline {subsection}{\numberline {10.5.1}Workflow}{91}{subsection.10.5.1}%
\contentsline {subsection}{\numberline {10.5.2}CCGA study}{92}{subsection.10.5.2}%
\contentsline {subsection}{\numberline {10.5.3}Deconvolution approaches}{92}{subsection.10.5.3}%
\contentsline {section}{\numberline {10.6}Targeted panel approaches for tumor content estimation}{93}{section.10.6}%
\contentsline {part}{II\hspace {1em}Papers}{94}{part.2}%
\contentsline {chapter}{\numberline {11}Role of non-coding sequence variants in cancer}{95}{chapter.11}%
\contentsline {section}{\numberline {11.1}Abstract}{95}{section.11.1}%
\contentsline {subsection}{\numberline {11.1.1}Introduction}{95}{subsection.11.1.1}%
\contentsline {section}{\numberline {11.2}Genomic sequence variants}{95}{section.11.2}%
\contentsline {section}{\numberline {11.3}Non-coding element annotation}{96}{section.11.3}%
\contentsline {subsection}{\numberline {11.3.1}Cis regulatory regions}{96}{subsection.11.3.1}%
\contentsline {subsection}{\numberline {11.3.2}Distal regulatory elements}{96}{subsection.11.3.2}%
\contentsline {subsection}{\numberline {11.3.3}RNA-seq}{96}{subsection.11.3.3}%
\contentsline {subsection}{\numberline {11.3.4}Transcribed pseudogenes}{96}{subsection.11.3.4}%
\contentsline {subsection}{\numberline {11.3.5}Evolutionary conservation}{97}{subsection.11.3.5}%
\contentsline {section}{\numberline {11.4}Roles for somatic variants in cancer}{97}{section.11.4}%
\contentsline {subsection}{\numberline {11.4.1}Gain of TF-binding sites}{97}{subsection.11.4.1}%
\contentsline {subsection}{\numberline {11.4.2}Fusion events due to genomic rearrangements}{97}{subsection.11.4.2}%
\contentsline {subsection}{\numberline {11.4.3}ncRNAs and their binding sites}{97}{subsection.11.4.3}%
\contentsline {subsection}{\numberline {11.4.4}Role of pseudogenes in modulating the expression of a parental gene}{98}{subsection.11.4.4}%
\contentsline {section}{\numberline {11.5}Roles for germline variants in cancer}{98}{section.11.5}%
\contentsline {subsection}{\numberline {11.5.1}Promoter mutations}{98}{subsection.11.5.1}%
\contentsline {subsection}{\numberline {11.5.2}SNPs in enhancers}{98}{subsection.11.5.2}%
\contentsline {subsection}{\numberline {11.5.3}Variants in introns}{98}{subsection.11.5.3}%
\contentsline {subsection}{\numberline {11.5.4}SNPs in ncRNA and their binding sites}{98}{subsection.11.5.4}%
\contentsline {subsection}{\numberline {11.5.5}Others}{98}{subsection.11.5.5}%
\contentsline {section}{\numberline {11.6}Interplay between germline and somatic variants}{98}{section.11.6}%
\contentsline {section}{\numberline {11.7}Computational methods for identifying variants}{99}{section.11.7}%
\contentsline {section}{\numberline {11.8}Experimental approaches for functional validation}{99}{section.11.8}%
\contentsline {chapter}{\numberline {12}Advances in understanding cancer genomics through second-generation sequencing}{101}{chapter.12}%
\contentsline {section}{\numberline {12.1}Abstract}{101}{section.12.1}%
\contentsline {subsection}{\numberline {12.1.1}Introduction}{101}{subsection.12.1.1}%
\contentsline {section}{\numberline {12.2}Cancer-specific consideration}{101}{section.12.2}%
\contentsline {subsection}{\numberline {12.2.1}Characteristics of cancer samples for genomic analysis}{102}{subsection.12.2.1}%
\contentsline {subsection}{\numberline {12.2.2}Structural variability of cancer genomes}{102}{subsection.12.2.2}%
\contentsline {section}{\numberline {12.3}Experimental approaches}{102}{section.12.3}%
\contentsline {subsection}{\numberline {12.3.1}Whole genome sequencing}{102}{subsection.12.3.1}%
\contentsline {subsection}{\numberline {12.3.2}Exome sequencing}{102}{subsection.12.3.2}%
\contentsline {subsection}{\numberline {12.3.3}Transcriptome sequencing}{103}{subsection.12.3.3}%
\contentsline {section}{\numberline {12.4}Detecting classes of genome alterations}{103}{section.12.4}%
\contentsline {subsection}{\numberline {12.4.1}Somatic nucleotide substitutions and small insertion and deletion mutations}{103}{subsection.12.4.1}%
\contentsline {subsection}{\numberline {12.4.2}Copy number}{103}{subsection.12.4.2}%
\contentsline {subsection}{\numberline {12.4.3}Chromosomal rearrangements}{103}{subsection.12.4.3}%
\contentsline {subsection}{\numberline {12.4.4}Microbe-discovery methods}{104}{subsection.12.4.4}%
\contentsline {section}{\numberline {12.5}Computational issues}{104}{section.12.5}%
\contentsline {subsection}{\numberline {12.5.1}Alignment and assembly}{104}{subsection.12.5.1}%
\contentsline {subsection}{\numberline {12.5.2}mutations detection}{104}{subsection.12.5.2}%
\contentsline {subsection}{\numberline {12.5.3}Validation of mutation and rearrangement calls}{104}{subsection.12.5.3}%
\contentsline {chapter}{\numberline {13}Integrative genomics viewer}{106}{chapter.13}%
\contentsline {section}{\numberline {13.1}Introduction}{106}{section.13.1}%
\contentsline {chapter}{\numberline {14}Tumour heterogeneity and resistance to cancer therapies}{107}{chapter.14}%
\contentsline {section}{\numberline {14.1}Abstract}{107}{section.14.1}%
\contentsline {subsection}{\numberline {14.1.1}Introduction}{107}{subsection.14.1.1}%
\contentsline {section}{\numberline {14.2}Causes of intratumoral heterogeneity}{107}{section.14.2}%
\contentsline {subsection}{\numberline {14.2.1}Genomic instability}{107}{subsection.14.2.1}%
\contentsline {subsection}{\numberline {14.2.2}The clonal evolution and selection hypothesis}{108}{subsection.14.2.2}%
\contentsline {section}{\numberline {14.3}The spectrum of tumour heterogeneity}{108}{section.14.3}%
\contentsline {subsection}{\numberline {14.3.1}Spatial heterogeneity}{108}{subsection.14.3.1}%
\contentsline {subsubsection}{\numberline {14.3.1.1}Heterogeneity at a single disease site}{108}{subsubsection.14.3.1.1}%
\contentsline {subsubsection}{\numberline {14.3.1.2}Comparison of spatially distinct disease sites}{108}{subsubsection.14.3.1.2}%
\contentsline {subsection}{\numberline {14.3.2}Temporal heterogeneity}{109}{subsection.14.3.2}%
\contentsline {subsubsection}{\numberline {14.3.2.1}Genomic complexity might increase with exposure to targeted therapies}{109}{subsubsection.14.3.2.1}%
\contentsline {subsubsection}{\numberline {14.3.2.2}Longitudinal sampling provides insight into temporal heterogeneity}{109}{subsubsection.14.3.2.2}%
\contentsline {subsubsection}{\numberline {14.3.2.3}Residual drug-tolerant cells can foster temporal heterogeneity}{109}{subsubsection.14.3.2.3}%
\contentsline {section}{\numberline {14.4}Noninvasive monitoring of heterogeneity}{110}{section.14.4}%
\contentsline {subsection}{\numberline {14.4.1}Analysis of ctDNA}{110}{subsection.14.4.1}%
\contentsline {section}{\numberline {14.5}Overcoming heterogeneity}{110}{section.14.5}%
\contentsline {chapter}{\numberline {15}Unravelling the clonal hierarchy of somatic genomic aberrations}{112}{chapter.15}%
\contentsline {section}{\numberline {15.1}Introduction}{112}{section.15.1}%
\contentsline {subsection}{\numberline {15.1.1}Abstract}{112}{subsection.15.1.1}%
\contentsline {subsection}{\numberline {15.1.2}Background}{112}{subsection.15.1.2}%
\contentsline {section}{\numberline {15.2}Results}{113}{section.15.2}%
\contentsline {subsection}{\numberline {15.2.1}Clonality assessment of aberrations from sequencing reads}{113}{subsection.15.2.1}%
\contentsline {subsection}{\numberline {15.2.2}Inferring the order of mutations in a tumour sample}{114}{subsection.15.2.2}%
\contentsline {subsection}{\numberline {15.2.3}In silico and in situ experimental validation}{114}{subsection.15.2.3}%
\contentsline {subsection}{\numberline {15.2.4}Comparative analysis reveals different mechanisms of tumour deregulation}{114}{subsection.15.2.4}%
\contentsline {subsection}{\numberline {15.2.5}Clonal hierarchy of genomic aberrations}{115}{subsection.15.2.5}%
\contentsline {section}{\numberline {15.3}Materials and methods}{115}{section.15.3}%
\contentsline {subsection}{\numberline {15.3.1}CLONET pipeline}{115}{subsection.15.3.1}%
\contentsline {subsection}{\numberline {15.3.2}CLONET on exome and targeted sequencing data}{115}{subsection.15.3.2}%
\contentsline {subsection}{\numberline {15.3.3}Expected distribution of the allelic fraction of a genomic segment}{115}{subsection.15.3.3}%
\contentsline {subsection}{\numberline {15.3.4}Estimated proportion of neutral reads for a genomic segment}{116}{subsection.15.3.4}%
\contentsline {subsection}{\numberline {15.3.5}From neutral to non-aberrant reads}{116}{subsection.15.3.5}%
\contentsline {subsection}{\numberline {15.3.6}From aberrant reads to aberrant cells}{116}{subsection.15.3.6}%
\contentsline {subsection}{\numberline {15.3.7}Uncertainty assessment and its propagation to clonality estimates}{117}{subsection.15.3.7}%
\contentsline {subsection}{\numberline {15.3.8}Clonality of bi-allelic deletion}{117}{subsection.15.3.8}%
\contentsline {chapter}{\numberline {16}TPES: timor purity estimation from SNVs}{118}{chapter.16}%
\contentsline {section}{\numberline {16.1}Abstract}{118}{section.16.1}%
\contentsline {subsection}{\numberline {16.1.1}Introduction}{118}{subsection.16.1.1}%
\contentsline {section}{\numberline {16.2}Materials and methods}{118}{section.16.2}%
\contentsline {chapter}{\numberline {17}SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines}{120}{chapter.17}%
\contentsline {section}{\numberline {17.1}Abstract}{120}{section.17.1}%
\contentsline {subsection}{\numberline {17.1.1}Introduction}{120}{subsection.17.1.1}%
\contentsline {section}{\numberline {17.2}Material and methods}{120}{section.17.2}%
\contentsline {subsection}{\numberline {17.2.1}Genotype distance}{120}{subsection.17.2.1}%
\contentsline {subsection}{\numberline {17.2.2}SNP panel selection procedure}{121}{subsection.17.2.2}%
\contentsline {subsection}{\numberline {17.2.3}SPIA probabilistic test on cell line genotype distance}{121}{subsection.17.2.3}%
